GEA
HELP

Glen Eagle Advisors’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Glen Eagle Advisors’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28
Closed -$247 – 1081
2024
Q4 		$247 Hold
28
– – ﹤0.01% 1060
2024
Q3 		$249 Sell
28
-1
-3% -$10 ﹤0.01% 1104
2024
Q2 		$297 Hold
29
– – ﹤0.01% 1088
2024
Q1 		$453 Hold
29
– – ﹤0.01% 1034
2023
Q4 		$449 Hold
29
– – ﹤0.01% 973
2023
Q3 		$579 Hold
29
– – ﹤0.01% 966
2023
Q2 		$414 Hold
29
– – ﹤0.01% 1015
2023
Q1 		$429 Hold
29
– – ﹤0.01% 1012
2022
Q4 		$335 Buy
29
+15
+107% +$247 ﹤0.01% 1100
2022
Q3 		$252 Hold
14
– – ﹤0.01% 1051
2022
Q2 		$290 Buy
+14
New +$339 ﹤0.01% 966

Other funds holding HELP

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Glen Eagle Advisors's HELP Position: Q1 2025 in Review

Glen Eagle Advisors sold out of Helus Pharma Inc. Common Stock (HELP) in Q1 2025, closing a stake of 28 shares — an estimated $247 sold.

Glen Eagle Advisors first reported a position in HELP in Q2 2022 and held it in 11 quarters. The position peaked at $579 in Q3 2023. 56 funds tracked by Wall St. Rank hold HELP as of Q1 2025.

  • Glen Eagle Advisors reported no remaining Helus Pharma Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Glen Eagle Advisors sold 28 Helus Pharma Inc. Common Stock shares in Q1 2025, an estimated $247.
  • Glen Eagle Advisors first reported a position in Helus Pharma Inc. Common Stock in Q2 2022 and held it in 11 quarters.
  • Glen Eagle Advisors's Helus Pharma Inc. Common Stock position peaked at $579 in Q3 2023.
  • 56 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q1 2025.

Based on Glen Eagle Advisors's 13F filing for Q1 2025, filed 15 May 2025.